Clarithromycin Pediatric Dosing
For pediatric patients >1 month of age, administer clarithromycin 15 mg/kg/day divided into 2 doses (maximum 1 gram/day), with duration varying by indication: 7 days for pertussis, 5-7 days for atypical pneumonia, and 5-10 days for other respiratory infections.
Standard Dosing Parameters
Age-Based Recommendations
- Infants <1 month: Contraindicated due to unknown risk of infantile hypertrophic pyloric stenosis (IHPS), similar to erythromycin 1
- Infants and children >1 month: 15 mg/kg/day in 2 divided doses 1, 2
- Maximum daily dose: 1 gram (500 mg twice daily) regardless of weight 1
Formulation
Clarithromycin is available as:
- Oral suspension (granules for reconstitution)
- Tablets (immediate-release)
- Extended-release tablets are not indicated for pediatric use 3
Administer with or without food - unlike the extended-release formulation, the immediate-release suspension does not require food administration 4.
Duration by Indication
The treatment duration depends on the specific infection:
Pertussis (Whooping Cough)
- 7 days 1
- This shorter course is as effective as longer regimens for eradicating Bordetella pertussis
Atypical Pneumonia
For Mycoplasma pneumoniae or Chlamydophila pneumoniae:
- 5 days when used as alternative therapy 2
- Azithromycin is preferred (5-day course), but clarithromycin 15 mg/kg/day in 2 doses is an acceptable alternative 2
Other Respiratory Infections
- 5-10 days depending on clinical response 5, 6, 7
- Studies support 5-day courses for pharyngitis and otitis media with comparable efficacy to 10-day penicillin regimens 5
Renal Impairment Adjustments
Critical consideration: Dosage adjustment is required for renal dysfunction 1, 3:
- Normal renal function: No adjustment needed
- Moderate impairment (CrCl 30-60 mL/min): Reduce dose by 50% if co-administered with atazanavir or ritonavir 3
- Severe impairment (CrCl <30 mL/min):
The CDC guidelines specifically note that "drug dosage and interval between doses should be reassessed in the presence of impaired renal function" 1. Unlike hepatic impairment (which requires no adjustment), renal dysfunction significantly affects clarithromycin clearance 8.
Important Safety Considerations
Contraindications
- History of hypersensitivity to any macrolide antibiotic 1
- Concomitant use with cisapride, pimozide, astemizole, or terfenadine (risk of fatal cardiac arrhythmias) 1
- Age <1 month (IHPS risk) 1
Drug Interactions
Clarithromycin is a potent CYP3A4 inhibitor 1, 8, 9. Exercise caution with:
- Statins metabolized by CYP3A4 (lovastatin, simvastatin)
- Immunosuppressants (cyclosporine, tacrolimus)
- Anticoagulants (warfarin)
- Benzodiazepines (midazolam, triazolam)
- Carbamazepine, theophylline, digoxin
Common Adverse Effects
Generally well-tolerated with 1, 5, 6:
- Gastrointestinal distress (most common): nausea, vomiting, diarrhea, abdominal cramps
- Taste disturbances
- Rare: hepatotoxicity, hypersensitivity reactions, anaphylaxis
Clinical Pearls
Bacteriological superiority: Clarithromycin demonstrates higher GABHS eradication rates (94%) compared to penicillin V (78%) despite similar clinical cure rates 5, 10. This may reduce transmission and recurrence risk.
Twice-daily dosing advantage: The 12-hour dosing interval improves adherence compared to three or four times daily regimens required for penicillin V or erythromycin 1, 5.
Tissue penetration: Clarithromycin achieves excellent concentrations in respiratory tissues, epithelial lining fluid, and alveolar macrophages, exceeding serum levels 8. This pharmacokinetic advantage supports its efficacy in respiratory infections.
Pregnancy category: FDA Category C - avoid in pregnancy unless benefits outweigh risks 1. This contrasts with erythromycin (Category B).